Health Economics Research Group, Brunel University, Uxbridge, UK.
Med Decis Making. 2010 Jul-Aug;30(4):E14-27. doi: 10.1177/0272989X10371134. Epub 2010 Jun 15.
Despite the huge cost of the program, the Centers for Medicare and Medicaid Services (CMS) has maintained a policy that cost-effectiveness is not considered in national coverage determinations (NCDs).
To assess whether an implicit cost-effectiveness threshold exists and to determine if economic evidence has been considered in previous NCDs.
A literature search was conducted to identify estimates of cost-effectiveness relevant to each NCD from 1999-2007 (n = 103). The economic evaluation that best represented each coverage decision was included in a review of the cost-effectiveness of medical interventions considered in NCDs.
Of the 64 coverage decisions determined to have a corresponding cost-effectiveness estimate, 49 were associated with a positive coverage decision and 15 with a noncoverage decision. Of the positive decisions, 20 were associated with an economic evaluation that estimated the intervention to be dominant (costs less and was more effective than the alternative), 12 with an incremental cost-effectiveness ratio (ICER) of less than $50,000, 8 with an ICER greater than $50,000 but less than $100,000, and 9 with an ICER greater than $100,000. Fourteen of the sample of 64 decision memos cited or discussed cost-effectiveness information.
CMS is covering a number of interventions that do not appear to be cost-effective, suggesting that resources could be allocated more efficiently. Although the authors identified several instances where cost-effectiveness evidence was cited in NCDs, they found no clear evidence of an implicit threshold.
尽管该项目耗资巨大,但医疗保险和医疗补助服务中心(CMS)仍维持着一项政策,即不考虑成本效益来进行国家覆盖范围的决定(NCD)。
评估是否存在隐含的成本效益阈值,并确定经济证据是否在以前的 NCD 中被考虑。
进行了文献检索,以确定从 1999 年至 2007 年与每项 NCD 相关的成本效益估计(n = 103)。将最能代表每个覆盖范围决策的经济评估纳入对 NCD 中考虑的医疗干预措施的成本效益审查中。
在确定有相应成本效益估计的 64 项覆盖范围决策中,49 项与积极的覆盖范围决策相关,15 项与非覆盖范围决策相关。在积极的决策中,有 20 项与估计干预措施具有优势(成本更低且比替代方案更有效)的经济评估相关,12 项与增量成本效益比(ICER)低于 50,000 美元相关,8 项与 ICER 大于 50,000 美元但小于 100,000 美元相关,9 项与 ICER 大于 100,000 美元相关。在 64 份决策备忘录样本中,有 14 份引用或讨论了成本效益信息。
CMS 正在覆盖许多似乎没有成本效益的干预措施,这表明资源可以更有效地分配。尽管作者在 NCD 中确定了几个引用成本效益证据的例子,但他们没有发现明确的隐含阈值的证据。